Pharmacological and non-pharmacological interventions in Down syndrome: a ClinicalTrials.gov-based analysis of completed studies with results

Abstract Background Down syndrome (DS) is a genetic condition associated with intellectual disability, cognitive impairment, and multiple comorbidities. Despite advances in supportive care, effective therapeutic interventions targeting cognitive and functional outcomes remain limited. This study aimed to analyze completed clinical trials with available results registered on ClinicalTrials.gov that investigate interventions for individuals with Down syndrome. Methods A retrospective registry-based analysis was conducted using ClinicalTrials.gov. Studies were included if they (1) involved Down syndrome, (2) were completed, and (3) reported results. Data extracted included study design, intervention type, enrollment size, and primary outcomes. Descriptive analysis was performed. Results A total of 34 studies met the inclusion criteria. The majority were interventional ( n = 33, 97%), with only one observational study (3%). Most trials were randomized controlled trials. Interventions included pharmacological therapies such as cognitive enhancers, behavioral interventions, nutritional supplementation, and supportive therapies. Enrollment sizes were generally small, with 23 studies (≈68%) enrolling fewer than 50 participants. Primary outcomes commonly focused on cognitive function, behavioral improvement, and safety. Conclusion Clinical trials in Down syndrome predominantly focus on interventional strategies targeting cognitive and functional outcomes. However, small sample sizes and heterogeneity in outcome measures limit generalizability. Greater standardization and larger-scale studies are needed to improve translational impact.

Authors

Institutions

Publication Details

Journal
Trials
Published
2026-11-13
DOI
https://doi.org/10.1186/s13063-026-10080-3
Primary Topic
Down syndrome and intellectual disability research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmacological and non-pharmacological interventions in Down syndrome: a ClinicalTrials.gov-based analysis of completed studies with results

Fahad S. Alshehri, Ahmed M. Ashour, Nasser M. Alorfi, Bader A. Alhazmi et al.
1 links
Trials
Down syndrome and intellectual disability research
article

Pharmacological and non-pharmacological interventions in Down syndrome: a ClinicalTrials.gov-based analysis of completed studies with results

Fahad S. Alshehri, Ahmed M. Ashour, Nasser M. Alorfi, Bader A. Alhazmi, Beisan A. Mohammad, Ali M. Alshahrani
article en

Abstract

Abstract Background Down syndrome (DS) is a genetic condition associated with intellectual disability, cognitive impairment, and multiple comorbidities. Despite advances in supportive care, effective therapeutic interventions targeting cognitive and functional outcomes remain limited. This study aimed to analyze completed clinical trials with available results registered on ClinicalTrials.gov that investigate interventions for individuals with Down syndrome. Methods A retrospective registry-based analysis was conducted using ClinicalTrials.gov. Studies were included if they (1) involved Down syndrome, (2) were completed, and (3) reported results. Data extracted included study design, intervention type, enrollment size, and primary outcomes. Descriptive analysis was performed. Results A total of 34 studies met the inclusion criteria. The majority were interventional ( n = 33, 97%), with only one observational study (3%). Most trials were randomized controlled trials. Interventions included pharmacological therapies such as cognitive enhancers, behavioral interventions, nutritional supplementation, and supportive therapies. Enrollment sizes were generally small, with 23 studies (≈68%) enrolling fewer than 50 participants. Primary outcomes commonly focused on cognitive function, behavioral improvement, and safety. Conclusion Clinical trials in Down syndrome predominantly focus on interventional strategies targeting cognitive and functional outcomes. However, small sample sizes and heterogeneity in outcome measures limit generalizability. Greater standardization and larger-scale studies are needed to improve translational impact.

Trials
Taif University (SA), Umm al-Qura University (SA), King Salman Center for Disability Research (SA), Fakeeh College for Medical Sciences (SA)
King Salman Center for Disability Research
Good health and well-being
Down syndrome and intellectual disability research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon